Group 1 - Meiansen announced the termination of its planned private placement to its controlling shareholder after nearly a year of planning, citing market conditions and company strategy as reasons for the decision [2] - The private placement was initially proposed on July 24, 2024, and approved by the shareholders on August 13, 2024, with the application submitted to the Shenzhen Stock Exchange on January 9, 2025 [2] - The controlling shareholder, Ma Yan, held only 15.42% of the shares before the planned issuance, and nearly half of his shares were pledged for financing as of the end of 2024 [2][3] Group 2 - The Shenzhen Stock Exchange requested details on Ma Yan's funding sources for the subscription, considering his financial status and the risks associated with high share pledges [3] - Ma Yan planned to finance the subscription primarily through further pledging of his shares, with intentions to raise up to 120 million yuan [3] - The proposed subscription price was 7.74 yuan per share, while the market price on the day of the inquiry response was 16.11 yuan, indicating a significant potential profit if the plan had proceeded [3] Group 3 - As of June 9, 2025, Meiansen's market capitalization was 3.894 billion yuan [5] - The company, established in May 2003 and listed on the Shenzhen Stock Exchange in November 2011, focuses on monitoring and warning technology and equipment in the safety sector [2] - In 2024, over 95% of Meiansen's revenue came from mining monitoring products, highlighting its strong market position in this niche [4]

Group 1 - Kaichun Co., Ltd. adjusted the share repurchase price limit from 26.625 yuan/share to 40 yuan/share, effective from June 10, 2025 [1] - Yipin Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, a Class 3 chemical drug used for sedation during anesthesia [1] - Bohui Innovation obtained a medical device registration certificate for HPV Genotyping Test Kit, used for qualitative detection of HPV DNA [1][2] Group 2 - Lingyi Zhi Zao's application for issuing convertible bonds and cash payment to acquire 66.46% of Jiangsu Kedasiteng Automotive Technology Co., Ltd. has been accepted by the Shenzhen Stock Exchange [3] - Kemin Food reported a 23.06% year-on-year increase in pig sales in May, with a total of 48,300 pigs sold [4][5] - Meian Sen decided to terminate the issuance of shares to specific objects due to market conditions and strategic considerations [6][7] Group 3 - Zhengbang Technology reported a 146.6% year-on-year increase in pig sales revenue in May, totaling 731 million yuan [9] - Yuanda Holdings plans to reduce the registered capital of its subsidiary from 73 million to 24.3 million USD to optimize asset structure [10] - East China Pharmaceutical's subsidiary received FDA approval for clinical trials of HDM1010 tablets for type 2 diabetes [12] Group 4 - Liangxin Co., Ltd. received a government subsidy of 14.1 million yuan, accounting for 4.52% of its audited net profit for 2024 [13] - Erkang Pharmaceutical's Vitamin B6 Injection passed the consistency evaluation for generic drugs [14] - New Industry received a patent certificate for an antibody related to anti-PIC detection, enhancing detection efficiency [16][15] Group 5 - Dongxing Medical signed a 6 million yuan technology development contract with Shanghai Jiao Tong University for collagen preparation processes [16] - Suchang Chai A's subsidiary will absorb and merge another subsidiary, adjusting internal equity structure [17] - Yibin Technology received a project designation notice from a domestic new energy vehicle company, with an estimated total sales of 256 million yuan over five years [18] Group 6 - Mingchen Health received a cash dividend of 20 million yuan from its subsidiary [19] - Hendi Pharmaceutical obtained a drug registration certificate for Ibuprofen Suspension, a common medication for children [19] - Huaren Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, classified as a Category B drug under national medical insurance [20] Group 7 - Enwei Pharmaceutical obtained a renewed drug production license for six key products [21] - Xiaoming Co., Ltd. reported a 45.59% year-on-year increase in chicken product sales in May, totaling 23.25 million birds [23][24] - Shan Natural Gas successfully issued a 350 million yuan short-term financing bond with a 1.78% interest rate [25] Group 8 - Xidamen announced plans for board members to reduce their holdings by up to 581,000 shares [26] - Shentong Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Saintno Bio plans to distribute a cash dividend of 0.14 yuan per share and a capital increase of 0.4 shares per share [28] Group 9 - *ST King Kong's subsidiary received a debt transfer notice from its controlling shareholder, totaling 364 million yuan [29] - Foxit Software's executives plan to reduce their holdings by a total of 55,800 shares [30] - Youyou Green Energy plans to apply for a bank credit line of up to 1.5 billion yuan [31] Group 10 - Guoxing Optoelectronics plans to distribute a cash dividend of 0.5 yuan per 10 shares [32] - Guangxun Technology plans to distribute a cash dividend of 2.6 yuan per 10 shares [33] - Hanrui Cobalt plans to distribute a cash dividend of 1.5 yuan per 10 shares [35] Group 11 - Tigermed plans to distribute a cash dividend of 3 yuan per 10 shares [37] - Shenliang Holdings plans to distribute a cash dividend of 1.5 yuan per 10 shares [38] - Yishitong plans to distribute a cash dividend of 1 yuan per 10 shares [39]

Group 1 - The core point of the announcement is that Chongqing Meiansen Technology Co., Ltd. has decided to terminate the issuance of shares to specific targets, and the decision was made in accordance with relevant laws and regulations [1][2]. - The supervisory board meeting was held on June 9, 2025, with all three supervisors present, and the decision was made through a voting process [1][2]. - The supervisory board concluded that the termination of the stock issuance process would not adversely affect the company's normal business operations and would not harm the interests of shareholders, especially minority shareholders [1]. Group 2 - The voting results for the resolution were unanimous, with three votes in favor and no votes against or abstaining [2]. - The announcement also references a detailed disclosure available on the official website, providing further information regarding the termination of the stock issuance [2].

证券代码：300275 证券简称：梅安森 公告编号：2025-055 重庆梅安森科技股份有限公司 关于公司终止向特定对象发行股票事项并撤回申请文件的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆梅安森科技股份有限公司（以下简称"梅安森"或"公司"）于 2025 年 6 月 9 日召开第六届董事会第六次会议和第六届监事会第五次会议，会议审议通过 了《关于公司终止向特定对象发行股票事项并撤回申请文件的议案》，同意公司 终止本次向特定对象发行股票事项并撤回申请文件。现将相关事项公告如下： 一、本次向特定对象发行股票事项的基本情况 2024 年 7 月 24 日，公司召开第五届董事会第二十八次会议和第五届监事会 第二十二次会议审议通过了《关于公司 2024 年度向特定对象发行股票方案的议 案》及相关事项。2024 年 8 月 13 日，公司召开 2024 年第二次临时股东大会审 议通过了本次向特定对象发行股票方案，并授权董事会全权办理本次向特定对象 发行股票相关事项。 义务。综合考虑当前市场环境、公司发展战略及经营规划等因素，经相关各方充 分沟通、审慎分析 ...

证券代码：300275 证券简称：梅安森 公告编号：2025-054 重庆梅安森科技股份有限公司 第六届监事会第五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆梅安森科技股份有限公司（以下简称"梅安森"或"公司"）第六届监 事会第五次会议通知于 2025 年 6 月 4 日以电子邮件方式发出，会议于 2025 年 6 月 9 日在公司会议室以现场方式召开。本次会议应出席监事三人，实际出席监事 三人。本次会议由公司监事会主席主持，董事会秘书列席了会议。本次会议的召 开符合有关法律、行政法规、部门规章、规范性文件和《公司章程》的有关规定， 所做决议合法有效。 一、本次监事会会议审议情况 经与会监事认真审议，会议在保证所有监事充分发表意见的前提下，以投票 表决的方式审议通过了以下议案： 1、审议通过《关于公司终止向特定对象发行股票事项并撤回申请文件的议案》 经审核，监事会认为：公司终止向特定对象发行股票事项的审议程序符合《公 司法》《证券法》等有关法律、法规以及《公司章程》的规定。该事项不会对公司 的正常业务经营产生不利影响，不存在损害公司及全 ...

证券代码：300275 证券简称：梅安森 公告编号：2025-053 重庆梅安森科技股份有限公司 第六届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆梅安森科技股份有限公司（以下简称"梅安森"或"公司"）第六届董 事会第六次会议通知于 2025 年 6 月 4 日以电子邮件方式发出，会议于 2025 年 6 月 9 日在公司会议室以现场与通讯表决相结合的方式召开。本次会议应出席董事 七人，实际出席董事七人（独立董事杨安富以通讯表决方式参加）。本次会议由 公司董事长主持，董事会秘书列席了会议。本次会议的召开符合有关法律、行政 法规、部门规章、规范性文件和《公司章程》的有关规定，所做决议合法有效。 一、本次董事会会议审议情况 经与会董事认真审议，会议在保证所有董事充分发表意见的前提下，以投票 表决的方式审议通过了以下议案： 1、审议通过《关于公司终止向特定对象发行股票事项并撤回申请文件的议 案》 综合考虑当前市场环境、公司发展战略及经营规划等因素，经相关各方充分 沟通、审慎分析后，公司决定终止本次向特定对象发行股票事项并撤回相关申请 ...

梅安森（300275）公告，公司于2025年6月9日召开董事会和监事会，审议通过了终止向特定对象发行股 票事项并撤回申请文件的议案。自2024年7月24日公司决定向特定对象发行股票以来，公司积极推进相 关工作，但综合考虑当前市场环境、公司发展战略及经营规划等因素，决定终止该事项。终止该事项不 会对公司当前正常生产经营产生重大不利影响。 ...

资金面上看，今日F5G概念板块获主力资金净流入8.40亿元，其中，22股获主力资金净流入，6股主力 资金净流入超5000万元，净流入资金居首的是中际旭创，今日主力资金净流入3.85亿元，净流入资金居 前的还有太辰光、华脉科技、仕佳光子等，主力资金分别净流入1.35亿元、1.18亿元、6732.82万元。 资金流入比率方面，华脉科技、意华股份、德科立等流入比率居前，主力资金净流入率分别为 43.87%、11.59%、7.94%。（数据宝） 截至6月4日收盘，F5G概念上涨2.35%，位居概念板块涨幅第10，板块内，33股上涨，华脉科技涨停， 太辰光、德科立、中际旭创等涨幅居前，分别上涨14.88%、11.56%、6.04%。跌幅居前的有四川九洲、 上港集团、梅安森等，分别下跌2.42%、1.20%、0.87%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 啤酒概念 | 3.85 | 兵装重组概念 | -0.34 | | 铜缆高速连接 | 2.90 | 草甘膦 | -0.26 | | 烟草 | 2.65 | ...

证券代码：300275 证券简称：梅安森 公告编号：2025-052 重庆梅安森科技股份有限公司 归属条件成就的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、本次符合归属条件的激励对象共计 89 人，归属的限制性股票数量为 251.136 万股，占目前公司股本总数的比例为 0.8230%。 2、归属股票来源：公司向激励对象定向发行 A 股普通股。 根据重庆梅安森科技股份有限公司（以下简称"公司"或"梅安森"）2021 年度股东大会的授权，公司于 2025 年 6 月 3 日召开第六届董事会第五次会议审 议通过了《关于公司 2022 年限制性股票激励计划第三个归属期归属条件成就的 议案》，现将有关事项说明如下： 一、2022 年限制性股票激励计划简述及已履行的审批程序 （一）公司 2022 年限制性股票激励计划简述 1、激励计划工具：第二类限制性股票 关于公司 2022 年限制性股票激励计划第三个归属期 3、2022 年 5 月 10 日，公司召开 2021 年度股东大会，审议通过了《<重庆 梅安森科技股份有限公司 2022 年限制性 ...

证券代码：300275 证券简称：梅安森 公告编号：2025-051 重庆梅安森科技股份有限公司 关于作废部分已授予但尚未归属的限制性股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆梅安森科技股份有限公司（以下简称"公司"或"梅安森"）于 2025 年 6 月 3 日召开董事会薪酬与考核委员会 2025 年第二次会议、第六届董事会第 五次会议和第六届监事会第四次会议审议通过了《关于作废部分已授予但尚未归 属的限制性股票的议案》，同意公司将 2 名激励对象已授予但尚未归属的 3.584 万股限制性股票失效作废，现将有关事项说明如下： 一、2022 年限制性股票激励计划已履行的审批程序 1、2022 年 4 月 18 日，公司召开第五届董事会第三次会议，审议通过了《< 重庆梅安森科技股份有限公司 2022 年限制性股票激励计划（草案）>及其摘要》 《重庆梅安森科技股份有限公司 2022 年限制性股票激励计划实施考核办法》及 《关于提请股东大会授权董事会办理公司 2022 年限制性股票激励计划相关事宜 的议案》等相关议案，公司拟以 6.58 元/股的 ...